Latest news with #Co.
Yahoo
26-05-2025
- Business
- Yahoo
World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial
SUZHOU, China, May 25, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) for a Phase I clinical trial, to treat spinal cord injury (SCI) — a severe and currently untreatable disease of the central nervous system, affecting more than 15 million patients globally. As the first regenerative clinical trial globally employing a subtype-specific neural progenitor cell therapeutic product to treat spinal cord injury, the study will be led by the Third Affiliated Hospital of Sun Yat-sen University, a nationally recognized leader in spinal cord injury treatment. Spinal cord injury (SCI) is a globally prevalent neurological disorder. It represents a critical unmet clinical need, marked by a high rate of disability, irreversibility, early onset, and a significant burden on patients, families, and society. SCI primarily affects young and middle-aged adults, typically resulting from traffic accidents, sports injuries, or other traumas. As a condition that deeply affects a patient's social function, it requires lifelong care and rehabilitation, leading to a significant economic burden and heavy societal costs. Beyond physical disability, SCI patients often face severe challenges in employment, social integration, and mental health. In high-income countries, lifetime healthcare and caregiving costs per patient may exceed USD 1 million, placing a heavy strain on both families and public health systems. Worldwide, over 15 million people are estimated to suffer from spinal cord injury (SCI). This figure includes over 3 million patients in China and 300,000 patients in the US. Each year, China and the US report approximately 100,000 and 18,000 new cases of acute or subacute SCI — equivalent to nearly 10 and 2 new cases every hour, respectively. SCI often leads to partial or complete paralysis, with the loss of motor and sensory function. Most patients experience permanent disability, severely compromising their quality of life. Due to the limited regenerative capacity of the central nervous system, nerve repair following SCI remains extremely challenging. Current treatments are largely limited to rehabilitation and supportive care, with no effective therapies available to promote neural regeneration during the injury phase. Following over four years of rigorous development and preclinical studies, XellSmart has partnered with leading clinical experts in spinal cord injury to initiate the world's first registrational clinical trial of an off-the-shelf, allogeneic, iPSC-derived, subtype-specific, regenerative neural cell therapy for spinal cord injury. This pioneering trial represents a landmark achievement in the global effort to develop regenerative therapies for spinal cord injury. Committed to advancing breakthrough treatments, XellSmart aims to redefine possibilities for SCI recovery — bringing a new hope to patients in China and around the world, and delivering tangible relief to families and communities affected by this devastating condition. For funding and BD cooperation, contact: BD@ XellSmart has been dedicated to the development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. Up until now, XellSmart has secured formal approvals from both China's NMPA and the U.S. FDA for seven registered and registrational clinical trials spanning China and the United States, for iPSC-derived cell therapies to treat CNS diseases — including Parkinson's disease (Approved Phase I in both China and US), amyotrophic lateral sclerosis (ALS; Approved Phase I in both China and US; Global orphan drug designation by FDA), and spinal cord injury (SCI; Approved Phase I in both China and US), hence pioneering breakthrough advancements in tackling major and severe CNS diseases: In 2023, China's first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, received FDA approval and was granted global orphan drug designation (ODD). In 2024, China's first national-level registered clinical study of iPSC-derived cell therapy for neurological diseases was approved to treat Parkinson's disease patients—including China's first case. More than 12 months of follow-up demonstrated good safety and significant improvements in "off" time, MDS-UPDRS scores, and multiple non-motor symptoms. In 2024, the world's first national-level registered clinical study of iPSC-derived cells (XS228 injection) for amyotrophic lateral sclerosis (ALS) was approved. Multiple ALS patients including the world's first case were treated safely, with preliminary data showing effective slowing of disease progression. In 2025, China's first allogeneic off-the-shelf iPSC-derived dopaminergic neural progenitor cell (XS411 injection) registrational Phase I clinical trial was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital, targeting Parkinson's disease — the world's second most common neurodegenerative disorder. In 2025, China's first randomized, double-blind controlled registrational Phase I/II clinical trial was launched, led by Huashan Hospital affiliated with Fudan University (also a National Neurological Disease Medical Center), targeting early-onset Parkinson's disease (EOPD). In 2025, the world's first registrational Phase I/II clinical trial of an allogeneic off-the-shelf iPSC-derived subtype-specific neural progenitor cell therapy (XS228 injection) was launched by Peking University Third Hospital, targeting amyotrophic lateral sclerosis (ALS), one of the world's four major incurable diseases. In 2025, the world's first registrational Phase I clinical trial of an allogeneic off-the-shelf iPSC-derived subtype-specific neural progenitor cell therapy was initiated by the Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI), a major neurological disease. XellSmart has established a fully dedicated, internationally competitive "All-In" team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. XellSmart has independently built and operates a R&D center, a B+A-grade GMP manufacturing facility and a quality control center with a total area exceeding 5000m2. Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple national, registered or registrational clinical studies and global clinical trials. XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others. For funding and BD cooperation, contact: BD@ View original content: SOURCE XellSmart Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hans India
24-05-2025
- Sport
- Hans India
I thought Rohit, Virat would quit after England tour: Vengsarkar
Mumbai: Former Indian cricketer Dilip Vengsarkar expressed his surprise at the retirements of batting stalwarts Rohit Sharma and Virat Kohli from the Test cricket, stating that he had thought the duo might call it a day after the upcoming England tour, scheduled to start from June 20. Both Rohit and Kohli retired from Test cricket earlier this month while continuing their careers in ODIs. Their departure left a huge void in the Indian Test team ahead of the new World Test Championship (WTC) cycle beginning with the all-important England tour. 'Both have outstanding and great cricketers, and their contribution to Indian cricket is huge. I was surprised because there is an England tour of five Test matches. I thought after the England tour, they might call it a day, but they preferred it before the England tour. Then I think it's their call,' Vengsarkar told IANS. Kohli bid adieu to his Test career with 9,230 runs in 123 matches at an impressive average of 46.85 with 30 centuries and 31 half-centuries, while Rohit drew curtains on his red-ball career with 4301 runs in 67 matches, including 12 centuries and 18 half-centuries, at an average of 40.57. In June 2024, Rohit and Kohli announced their retirement from T20Is after India beat South Africa to win the 2024 Men's T20 World Cup. Vengsarkar feels that the first two Tests of the five-match series against England will be crucial for the visiting side on the challenging tour, starting on June 20 'Both are experienced players, and they have done so well in England on every tour, so it's a big loss. Then, if you see that other players have done well for the India A team, in first-class cricket in India, they will get an opportunity to play and establish themselves in the Indian team,' he added. Rohit's retirement means that a new skipper will be in place for the Indian team when they tour England for a five-match Test series starting on June 20. Asked about who will fill the void left in the Indian Test cricket set-up with Rohit and Kohli's departure, Vengasarkar said, 'It is difficult to say who will replace them because it is up to (Ajit Agarkar) and Co. as they are selectors. They are observing FC matches (Irani Cup, Ranji Trophy, Duleep Trophy), and I think it's all up to them (selectors).' Vengasarkar then showered praises on Shreyas Iyer for his current form. Iyer had a successful outing with the bat at the Champions Trophy 2025 in March, scoring 243 runs in five games at an average of 48.60. He carried his fine form into the IPL 2025, where he led his side (Punjab Kings) from the front as PBKS reached the playoffs for the first time in 11 years. In the process, Iyer became the first captain to lead three different franchises into the IPL playoffs (Delhi Capitals in 2020 and Kolkata Knight Riders in 2024). Iyer's runs tally in the IPL 2025 currently stands at 435, including two half-centuries. 'He is a good player, there is no question about it and he's done very well over the years, he is an experienced player,' said the veteran on being asked if Iyer's current form can help him fill the void left created after Kohli's retirement from the T20I and Test formats.
Yahoo
23-05-2025
- Business
- Yahoo
Liebherr expands scientific portfolio with new combination refrigerator-freezer for research and laboratory needs
Liebherr refrigerators and freezers introduces new combination refrigerator-freezer expanding current scientific and healthcare portfolio to meet the needs of healthcare, biotechnology and pharma industries. MIAMI, May 23, 2025 /PRNewswire/ -- Liebherr USA, Co. refrigerators and freezers is excited to announce the addition of a new combination refrigerator-freezer to its scientific appliance lineup. This innovative appliance has been specifically engineered to meet the stringent demands of research and laboratory environments, serving industries such as healthcare, biotechnology, and pharmaceuticals. It offers enhanced safety, reliability, and compliance with industry standards, all while providing ease of use for daily operations. Alex Squarize, Divisional Director of refrigerators and freezers at Liebherr USA, Co. shares, "The addition of this new refrigerator-freezer combination marks an exciting expansion of Liebherr's product range, reinforcing our commitment to delivering top-tier solutions for laboratories, universities, and corporate research teams. This new product reflects our dedication to meeting the unique needs of our customers and setting new benchmarks for performance, reliability, and durability in the scientific equipment industry." Tailored solutions for demanding applications Designed to ensure precise temperature control, the new combination refrigerator-freezer maintains maximum stability, keeping the refrigerator compartment within ±3°C of the set temperature, and the freezer compartment within ±5°C. Multiple alarm functions safeguard against unanticipated temperature fluctuations, enabling quick responses to protect the integrity of sensitive materials. In the event of a malfunction causing the temperature to drop below +2°C, the integrated SafetyDevice system takes over, preventing the contents from freezing. Additionally, the appliance can be connected to a monitoring system through WiFi/LAN, ensuring continuous documentation and real-time monitoring to address potential risks proactively. With the addition of an external data logger, Liebherr's new combination appliance, as well as those from other manufacturers, can now easily connect to the SmartMonitoring system. Designed for convenience and hygiene The new combination's design prioritizes user-friendliness with intuitive menu navigation for effortless operation. An antibacterial lever handle and an easy-to-clean interior enhance both convenience and hygiene. Furthermore, the appliance doors automatically open beyond a 90° angle, simplifying the loading and unloading process and improving workflow efficiency. Uncompromising safety and compliance The SCFvh 4032 model, part of Liebherr's Perfection series, is built with a strong focus on safety and adheres to key industry standards, including IEC 61010-2-011 and DIN 13277. This appliance is ideal for general laboratory use, offering reliability and consistency to meet the needs of demanding environments. The SCFvh 4032 will be available in March 2025. Read more at About Liebherr USA, Co. Liebherr USA, Co. based in Newport News, VA provides sales and service on behalf of ten different Liebherr product segments: earthmoving, material handling, mining, mobile and crawler cranes, tower cranes, concrete technology, deep foundation machines, maritime cranes; components, and refrigeration and freezing. About the Liebherr Group – 75 years of moving forward The Liebherr Group is a family-run technology company with a highly diversified product portfolio. The company is one of the largest manufacturers of construction equipment in the world. It also provides high-quality, user-oriented products and services in a wide range of other areas. The Liebherr Group includes over 150 companies across all continents. In 2023, it employed more than 50,000 staff and achieved combined revenues of over 14 billion euros. Liebherr was founded by Hans Liebherr in 1949 in the southern German town of Kirchdorf an der Iller. Since then, the staff have been pursuing the goal of achieving continuous technological innovation, and bringing industry-leading solutions to its customers. Under the slogan '75 years of moving forward', the Group celebrates its 75th anniversary in 2024. Contact Silvia PuigdemontRegional Product Manager Liebherr USA, and FreezersPhone: +1 305-817-7500E-mail: Ana Cabiedes Head of Marketing Liebherr USA, Co.E-Mail: Published by Liebherr USA, News / View original content to download multimedia: SOURCE Liebherr Appliances USA
NDTV
23-05-2025
- Sport
- NDTV
"Thought They Might Call It A Day After England Tests": Ex-India Star On Rohit Sharma, Virat Kohli's Retirement
Former Indian cricketer Dilip Vengsarkar expressed his surprise at the retirements of batting stalwarts Rohit Sharma and Virat Kohli from the Test cricket, stating that he had thought the duo might call it a day after the upcoming England tour, scheduled to start from June 20. Both Rohit and Kohli retired from Test cricket earlier this month while continuing their careers in ODIs. Their departure left a huge void in the Indian Test team ahead of the new World Test Championship (WTC) cycle beginning with the all-important England tour. "Both have outstanding and great cricketers, and their contribution to Indian cricket is huge. I was surprised because there is an England tour of five Test matches. I thought after the England tour, they might call it a day, but they preferred it before the England tour. Then I think it's their call," Vengsarkar told IANS. Kohli bid adieu to his Test career with 9,230 runs in 123 matches at an impressive average of 46.85 with 30 centuries and 31 half-centuries, while Rohit drew curtains on his red-ball career with 4301 runs in 67 matches, including 12 centuries and 18 half-centuries, at an average of 40.57. In June 2024, Rohit and Kohli announced their retirement from T20Is after India beat South Africa to win the 2024 Men's T20 World Cup. "Both are experienced players, and they have done so well in England on every tour, so it's a big loss. Then, if you see that other players have done well for the India A team, in first-class cricket in India, they will get an opportunity to play and establish themselves in the Indian team," he added. Rohit's retirement means that a new skipper will be in place for the Indian team when they tour England for a five-match Test series starting on June 20. Asked about who will fill the void left in the Indian Test cricket set-up with Rohit and Kohli's departure, Vengasarkar said, "It is difficult to say who will replace them because it is up to (Ajit Agarkar) and Co. as they are selectors. They are observing FC matches (Irani Cup, Ranji Trophy, Duleep Trophy), and I think it's all up to them (selectors)." Vengasarkar then showered praises on Shreyas Iyer for his current form. Iyer had a successful outing with the bat at the Champions Trophy 2025 in March, scoring 243 runs in five games at an average of 48.60. He carried his fine form into the IPL 2025, where he led his side (Punjab Kings) from the front as PBKS reached the playoffs for the first time in 11 years. In the process, Iyer became the first captain to lead three different franchises into the IPL playoffs (Delhi Capitals in 2020 and Kolkata Knight Riders in 2024). Iyer's runs tally in the IPL 2025 currently stands at 435, including two half-centuries. "He is a good player, there is no question about it and he's done very well over the years, he is an experienced player," said the veteran on being asked if Iyer's current form can help him fill the void left created after Kohli's retirement from the T20I and Test formats. Listen to the latest songs, only on
Yahoo
23-05-2025
- Business
- Yahoo
COSCO SHIPPING International (Singapore) (SGX:F83) investors are sitting on a loss of 39% if they invested five years ago
For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term COSCO SHIPPING International (Singapore) Co., Ltd. (SGX:F83) shareholders for doubting their decision to hold, with the stock down 39% over a half decade. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the five years over which the share price declined, COSCO SHIPPING International (Singapore)'s earnings per share (EPS) dropped by 5.8% each year. Readers should note that the share price has fallen faster than the EPS, at a rate of 9% per year, over the period. So it seems the market was too confident about the business, in the past. Having said that, the market is still optimistic, given the P/E ratio of 51.54. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). It might be well worthwhile taking a look at our free report on COSCO SHIPPING International (Singapore)'s earnings, revenue and cash flow. Investors in COSCO SHIPPING International (Singapore) had a tough year, with a total loss of 13%, against a market gain of about 21%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 7% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with COSCO SHIPPING International (Singapore) , and understanding them should be part of your investment process. Of course COSCO SHIPPING International (Singapore) may not be the best stock to buy. So you may wish to see this free collection of growth stocks. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Singaporean exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
